CorMedix Inc.
CRMD | NASDAQ
$7.77
+$0.05 (+0.65%)
At close: Sep 21, 2026, 4:00 PM ET
$7.77
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Company Profile
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Joseph Todisco | CEO & Chairman of the Board of Directors |
| Susan Blum | Executive Vice President & Chief Financial Officer |
| Beth Steinbrenner | SVP & Chief Human Resource Officer |
| Donna Ucci | Senior Vice President & Head of Global Quality |
| Elizabeth Hurlburt | Executive VP and Chief Operating & Commercial Officer |
| Jared L. Crandon | Executive Director of Clinical Portfolio Management |
| Kaufman Beth Zelnick | EVP, Chief Legal and Compliance Officer & Corporate Secretary |
| Matthew T. David | EVP & Chief Business Officer |
| Michael Seckler | Executive Vice President & Chief Commercial Officer |
| Peter Sullivan BCOP | Senior Vice President of Market Access |
| Tushar Mukherjee | Senior Vice President & Head of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 8-K | Current Report |
| Jul 02, 2026 | 8-K | Current Report |
| Jul 01, 2026 | 8-K | Current Report |
| Jun 25, 2026 | S-8 POS | Filing |
| Jun 24, 2026 | 8-K | Current Report |
CorMedix Inc.
| Country | United States |
| IPO Date | May 12, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 191 |
| CEO | Joseph Todisco |
Contact Details
389 Interpace Pkwy Parsippany,
New Jersey 07054 United States
Stock Details
| Ticker Symbol | CRMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001410098 |
| CUSIP Number | 21900C308 |
| ISIN Number | US21900C3088 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove CRMD